Skip to the guide

Care explained, one question at a time.

Use this guide to explore care choices; it is not a clinic.

Human evidence

What the human studies can tell you

Ask what was tested in people, how it was tested and what remains unknown. Adding a study to a public list does not show what it found.

  1. Look at the size of the evidence.

    The US drug-review agency is FDA, which stands for Food and Drug Administration.

    In the September 2026 record, FDA’s review found five human studies, with roughly 80 people receiving BPC-157 across them. FDA human-study summary

    Only two had a comparison group; their reports were short summaries for research meetings, with no full study papers published.

    A comparison group gives researchers something to compare the treatment against.

  2. Read the bowel-disease result narrowly.

    A short trial compared BPC-157 with a dummy treatment for ulcerative colitis, a bowel disease.

    FDA said the study’s results were not strong enough to show that BPC-157 helped people with that bowel disease or was safe for that use. FDA trial assessment

    That is a limit on the evidence, not proof that the substance has no effect.

  3. Notice what the small reports lacked.

    Small reports looked at knee pain, a painful bladder condition and a drip into a vein, with no comparison group.

    Some participants reported improvement, but those reports cannot establish that BPC-157 caused it. FDA study review

  4. Check whether a planned trial has results.

    In September 2026, the public study list showed a trial in China for hamstring injuries, meaning injuries to muscles along the back of the thigh. Government trial records

    That trial was still seeking people and had no results.

    A US study after shoulder surgery was not yet seeking people and also had no results.

    A plan to test a treatment does not establish that it works.